Litigation Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Docket		Date Filed	2011-02-09
Court	District Court, D. New Jersey	Date Terminated	2013-06-03
Cause	35:145 Patent Infringement	Assigned To	Joel A. Pisano
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	HANMI USA, INC.
Patents	6,875,872; 7,411,070
Attorneys	JONATHAN M.H. SHORT
Link to Docket	External link to docket

Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-02-09				External link to document

AstraZeneca AB v. Hanmi USA, Inc. Litigation Summary and Patent Analysis

Last updated: September 25, 2026

AstraZeneca AB v. Hanmi USA, Inc., No. 3:11-cv-00760, was a Hatch-Waxman patent case in the U.S. District Court for the District of New Jersey involving Hanmi's proposed generic version of AstraZeneca's Nexium product, esomeprazole magnesium delayed-release capsules. The case arose from Hanmi's Paragraph IV certification and challenged AstraZeneca's patents covering esomeprazole and its pharmaceutical formulation. The matter was resolved without a reported merits judgment establishing generic invalidity or noninfringement. The commercial effect was limited by the finite life of AstraZeneca's core Nexium patent protection and the broader generic-entry timetable for esomeprazole.

What drug and ANDA were involved in AstraZeneca v. Hanmi?

The litigation concerned esomeprazole magnesium, the active pharmaceutical ingredient in Nexium. Nexium is a proton-pump inhibitor approved for acid-related gastrointestinal conditions, including gastroesophageal reflux disease, erosive esophagitis and maintenance treatment.

Hanmi's product was a proposed generic delayed-release oral dosage form. The delayed-release design is important because esomeprazole is acid-labile. The product must prevent release in the stomach and deliver the active ingredient in the intestine.

Item	Case information
Brand product	Nexium
Active ingredient	Esomeprazole magnesium
Product class	Proton-pump inhibitor
Proposed generic	Esomeprazole magnesium delayed-release capsules
Plaintiff	AstraZeneca AB, with AstraZeneca-affiliated entities
Defendant	Hanmi USA, Inc.
Court	U.S. District Court for the District of New Jersey
Case number	3:11-cv-00760
Legal pathway	Hatch-Waxman patent litigation
Trigger	Hanmi ANDA filing with Paragraph IV certifications
Ultimate resolution	Settlement or other non-merits termination, with no reported final trial judgment

The case was a small-molecule generic dispute, not a biologic or biosimilar case. The relevant FDA pathway was an Abbreviated New Drug Application, not a Biologics License Application or a biosimilar application under the Public Health Service Act.

What patents protected Nexium in the Hanmi litigation?

AstraZeneca's Nexium patent estate included composition-of-matter, salt, formulation and manufacturing-related patents. The patents most closely associated with the Nexium patent program included the following:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 5,714,504	Optically pure substituted benzimidazole compounds and salts	Core esomeprazole protection
U.S. Patent No. 5,877,192	Esomeprazole-related pharmaceutical compounds and salts	Product and salt protection
U.S. Patent No. 6,369,085	Pharmaceutical compositions involving proton-pump inhibitors	Formulation protection
U.S. Patent No. 6,875,872	Pharmaceutical dosage forms containing acid-sensitive proton-pump inhibitors	Delayed-release formulation protection
Other listed patents	Formulation, dosage-form and method-of-use claims	Secondary barriers to entry

The asserted-patent scope in a Hatch-Waxman action depends on the patents identified in AstraZeneca's complaint and the Orange Book certifications made by Hanmi. Not every patent in AstraZeneca's broader Nexium portfolio necessarily was asserted against Hanmi.

AstraZeneca's litigation theory would have focused on the statutory act of infringement created by Hanmi's ANDA filing under 35 U.S.C. § 271(e)(2), rather than on commercial sales. The central questions were whether Hanmi's proposed product would infringe the asserted claims and whether those claims were valid and enforceable.

When did Nexium lose exclusivity?

Nexium did not have a single exclusivity date. Its commercial protection came from several overlapping rights:

1. New chemical entity and FDA exclusivity.
2. Composition and salt patents.
3. Delayed-release formulation patents.
4. Pediatric exclusivity.
5. Method-of-use patents.
6. Litigation-triggered regulatory stays.

The core U.S. patent frequently associated with esomeprazole, U.S. Patent No. 5,714,504, had an expiration date in 2014, subject to applicable patent-term adjustment or extension and pediatric exclusivity. The practical generic-entry date depended on the patent claims challenged, the validity of later formulation patents and any settlement terms.

Exclusivity component	Commercial effect
Core esomeprazole patent	Protected the active pharmaceutical product during the principal patent term
Formulation patents	Could delay or complicate approval of products using the claimed dosage architecture
Method-of-use patents	Could support partial labeling restrictions or litigation over specific indications
Pediatric exclusivity	Could add six months to eligible patent or exclusivity periods
ANDA litigation stay	Could delay FDA approval for up to 30 months after service of a Paragraph IV notice, subject to statutory exceptions

The loss of core product protection did not automatically eliminate all formulation or method-of-use barriers. In practice, however, proton-pump inhibitors face substantial price erosion once multiple ANDA products are approved.

What was Hanmi's Paragraph IV challenge?

Hanmi's ANDA filing reportedly included Paragraph IV certifications against AstraZeneca's listed Nexium patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

AstraZeneca's filing of the infringement action created the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the stay was shortened or terminated. The litigation therefore had two direct commercial consequences:

• It postponed potential FDA approval of Hanmi's ANDA.
• It forced AstraZeneca to defend the validity and scope of the Nexium patent estate before generic entry.

A Paragraph IV filing does not itself establish that a generic will launch. The applicant must still satisfy FDA requirements concerning bioequivalence, chemistry, manufacturing and controls, labeling and manufacturing-site compliance.

What was the litigation status and outcome?

The case did not produce a widely cited trial decision invalidating the Nexium patents or confirming that Hanmi's proposed product was noninfringing. The docket-level outcome was a non-merits resolution rather than a public appellate ruling that materially changed the law governing esomeprazole patents.

That outcome has several implications:

• AstraZeneca avoided a public adverse merits judgment in the Hanmi case.
• Hanmi did not obtain a reported judicial determination that the asserted patents were invalid.
• The case did not create binding precedent on esomeprazole claim construction.
• Generic-entry timing was governed primarily by the parties' resolution, FDA approval status and the remaining patent and regulatory barriers.

A settlement in a Hatch-Waxman case can permit an agreed launch date before the last nominal patent expiry. Unless the agreement terms are publicly available and submitted under the Medicare Modernization Act's patent-settlement reporting requirements, the exact entry date, compensation terms and restrictions may not be apparent from the complaint or dismissal order alone.

Did the case involve formulation patents?

Yes. Formulation protection was commercially important because esomeprazole is acid-sensitive. AstraZeneca's Nexium formulation used delayed-release technology to protect the active ingredient from gastric degradation.

Relevant formulation issues included:

• Enteric protection.
• Release of esomeprazole at an intestinal pH.
• The structure of the dosage form.
• The use of pellets, granules or multiparticulate systems.
• The composition and arrangement of pharmaceutical excipients.
• Stability and dissolution characteristics.
• Whether Hanmi's proposed product practiced the asserted formulation claims.

A formulation patent is narrower than a composition-of-matter patent. It may block a specific dosage architecture without preventing every alternative esomeprazole formulation. Generic manufacturers can reduce risk by using different excipients, coating materials, pellet structures or release profiles, although those changes must remain bioequivalent and acceptable to FDA.

Did method-of-use patents affect the case?

Method-of-use patents can create a separate infringement risk even when a generic applicant seeks approval for a narrower label. AstraZeneca's Nexium portfolio included patents relating to the treatment and management of acid-related disorders.

The main legal issue is whether the proposed labeling induces infringement under 35 U.S.C. § 271(b). A generic applicant may use a "skinny label" that omits patented indications. That strategy does not eliminate risk if the remaining label, prescribing information or product use encourages the patented method.

For Nexium, method-of-use claims were less commercially durable than the core product and formulation claims because proton-pump inhibitors have broad overlapping clinical uses and generic substitution occurs at the pharmacy level.

How strong was AstraZeneca's patent estate?

AstraZeneca's patent estate was strong during the period when the core composition and delayed-release patents remained in force. Its principal advantages were:

• A commercially important active ingredient with established clinical demand.
• Multiple patent categories rather than reliance on one claim set.
• A formulation that required technically specific delayed release.
• The ability to invoke the 30-month ANDA stay.
• A large branded market that justified extensive litigation.

The estate weakened as the core patent expired and multiple generic applicants challenged the remaining patents. Formulation claims generally presented more limited exclusionary power than composition claims because alternative manufacturing routes could be developed.

Risk factor	Assessment
Core product patent	High value before expiration; sharply reduced after expiry
Formulation patents	Moderate value; dependent on claim construction and product design
Method-of-use patents	Moderate to low commercial value where skinny labeling was feasible
Manufacturing know-how	Potentially meaningful but difficult to enforce against a legally different process
Litigation leverage	Strong during the statutory stay; reduced once multiple generics approached approval
Post-expiry market protection	Limited after several ANDAs were approved

What manufacturing and intellectual-property barriers applied?

Esomeprazole manufacturing requires control over stereochemistry, salt formation, particle or pellet properties, coating uniformity, dissolution and stability. Those technical requirements can create operational barriers even when patent protection is limited.

The main barriers were:

• Consistent production of the esomeprazole magnesium salt.
• Control of acid degradation.
• Reproducible enteric coating.
• Bioequivalence across commercial batches.
• FDA inspection readiness.
• Avoidance of patented formulation combinations.
• Reliable supply of qualified active pharmaceutical ingredient.

These barriers are not equivalent to patent exclusivity. A manufacturer may have freedom to operate while still facing high development, validation and regulatory costs.

How did AstraZeneca v. Hanmi compare with generic-entry risk for Nexium?

The Hanmi case was one element of a larger multi-applicant challenge to Nexium. The competitive threat increased as more ANDA applicants filed Paragraph IV certifications.

Scenario	Effect on AstraZeneca
One applicant settles for delayed entry	Preserves some branded revenue and limits immediate price erosion
Several applicants receive approval on the same date	Accelerates generic substitution and price compression
Core patent invalidated	Creates early and potentially broad entry
Formulation patent survives	May delay or narrow entry for products using the claimed formulation
Skinny-label approval	Permits entry for unpatented indications while preserving some method claims
Authorized generic launch	Allows AstraZeneca to capture part of the post-entry market through a licensed generic

Nexium's commercial exposure was material because the product was a major branded gastrointestinal medicine. Once multiple generic esomeprazole products became available, expected revenue protection depended more on launch timing, payer contracting, authorized-generic strategy and brand loyalty than on the original composition patent.

What is the Orange Book status of Nexium?

The FDA Orange Book identifies patents and exclusivity associated with approved drug products. For Nexium, the relevant listings included patents directed to esomeprazole and delayed-release pharmaceutical formulations. Orange Book listings formed the basis for Hanmi's patent certifications and AstraZeneca's statutory infringement action.

The Orange Book does not determine patent validity. It records the sponsor's listed patents and provides the regulatory framework for ANDA certifications. A listed patent can later be narrowed, invalidated, delisted or rendered commercially ineffective by expiration.

For diligence purposes, the Orange Book should be reviewed alongside:

• The specific ANDA certification.
• The complaint and amended complaint.
• The patent claims actually asserted.
• Any claim-construction decisions.
• The settlement or dismissal documents.
• FDA approval records for Hanmi and competing applicants.

Did the case involve biosimilar risk?

No. Biosimilar risk was not implicated. Esomeprazole is a chemically synthesized small molecule regulated through the ANDA pathway. The principal competitive risks were generic substitution, Paragraph IV litigation and formulation design-around.

The case therefore differs from biologic patent disputes involving:

• Patent dance procedures.
• Interchangeability designations.
• Biosimilar reference-product exclusivity.
• Manufacturing-cell-line patents.
• Regulatory exclusivity under the Biologics Price Competition and Innovation Act.

Key Takeaways

• AstraZeneca AB v. Hanmi USA, No. 3:11-cv-00760, was a Hatch-Waxman case concerning Hanmi's proposed generic esomeprazole magnesium delayed-release capsules.
• AstraZeneca relied on a Nexium patent estate covering the active ingredient, salt, delayed-release formulation and related uses.
• Hanmi's Paragraph IV certifications triggered patent litigation and the statutory FDA approval stay.
• The case ended without a reported merits ruling invalidating AstraZeneca's Nexium patents or establishing Hanmi's noninfringement.
• The core commercial protection for esomeprazole weakened materially after expiration of the principal composition patent and the arrival of multiple generic competitors.
• Formulation patents created additional entry risk but were narrower and more vulnerable to design-around than core product claims.
• The dispute involved generic, not biosimilar, competition.

FAQs About AstraZeneca AB v. Hanmi USA

What was the drug in AstraZeneca v. Hanmi USA?

The dispute involved esomeprazole magnesium, the active ingredient in AstraZeneca's Nexium delayed-release capsules.

Was Hanmi allowed to launch a generic Nexium product?

The public litigation record does not establish a reported court-ordered launch right. Generic entry depended on FDA approval, the patent settlement or dismissal terms and expiration of applicable patent and exclusivity rights.

Did AstraZeneca win the case at trial?

No reported final merits judgment establishes that AstraZeneca won at trial or that Hanmi's ANDA product infringed valid patent claims.

Was U.S. Patent No. 5,714,504 important to Nexium?

Yes. The patent was among the principal patents associated with esomeprazole and provided important early protection for AstraZeneca's product.

Is an esomeprazole generic a biosimilar?

No. Esomeprazole is a small-molecule drug. Its generic versions are approved through the ANDA pathway and evaluated primarily through pharmaceutical equivalence and bioequivalence standards.

References

1. AstraZeneca AB v. Hanmi USA, Inc., No. 3:11-cv-00760, U.S. District Court for the District of New Jersey (2011).

2. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. Hatch, W. M. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

4. U.S. Patent No. 5,714,504. (1998). Optically pure salts of substituted benzimidazoles.

5. U.S. Patent No. 6,875,872. (2005). Pharmaceutical dosage form comprising an acid-sensitive proton pump inhibitor.

6. 21 U.S.C. § 355(j).

7. 35 U.S.C. §§ 271(e)(2), 271(b).